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Abstract
Background: Poor adherence to treatment is common in patients on hemodialysis which may increase risk for poor
clinical outcomes and mortality. Self management interventions have been shown to be effective in improving
compliance in other chronic populations. The aim of this trial is to evaluate the effectiveness of a recently developed
group based self management intervention for hemodialysis patients compared to standard care.
Methods/Design: This is a multicentre parallel arm block randomized controlled trial (RCT) of a four session group
self management intervention for hemodialysis patients delivered by health care professionals compared to
standard care. A total of 176 consenting adults maintained on hemodialysis for a minimum of 6 months will be
randomized to receive the self management intervention or standard care. Primary outcomes are biochemical
markers of clinical status and adherence. Secondary outcomes include general health related quality of life, disease-
specific quality of life, mood, self efficacy and self-reported adherence. Outcomes will be measured at baseline,
immediately post-intervention and at 3 and 9 months post-intervention by an independent assessor and analysed
on intention to treat principles with linear mixed-effects models across all time points. A qualitative component
will examine which aspects of program participants found particularly useful and any barriers to change.
Discussion: The NKF-NUS intervention builds upon previous research emphasizing the importance of empowering
patients in taking control of their treatment management. The trial design addresses weaknesses of previous
research by use of an adequate sample size to detect clinically significant changes in biochemical markers,
recruitment of a sufficiently large representative sample, a theory based intervention and careful assessment of
both clinical and psychological endpoints at various follow up points. Inclusion of multiple dependent variables
allows us to assess the broader impact on the intervention including both hard end points as well as patient
reported outcomes. This program, if found to be effective, has the potential to be implemented within the existing
renal services delivery model in Singapore, particularly as this is being delivered by health care professionals
already working with hemodialysis patients in these settings who are specifically trained in facilitating self
management in renal patients.
Trial registration: Current Controlled Trials ISRTN31434033
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Background
End stage renal disease (ESRD) is a complex disease
associated with compromised quality of life (QoL),
unplanned hospital admissions, high mortality and
therefore high burden of illness [1,2]. With rising preva-
lence worldwide, the growth of ESRD populations has
been a concern for many countries, as ESRD consumes
increasing proportions of healthcare budgets [3,4]. The
burden of ESRD will increase with the growth of the
ageing population [5,6] and increased prevalence of dia-
betes [7].
As in other countries the incidence and prevalence of
ESRD in Singapore is rising [7]. The incidence rate has
inflated from 194.0 per million population (pmp) to
284.9 pmp from 1999 to 2007 [8]. This increase has
been standardized for age differences between the popu-
lation cohorts and hence is an underestimate as there is
an escalation in the elderly population of Singapore. Sin-
gapore has one of the fastest aging populations in the
world. When elderly is defined as a person of 65 years
of age and above, the number of elderly has expanded
from 47,200 in 1965 to 330,000 in 2009 [9]. This rapid
expansion of the elderly in Singapore will have a signifi-
cant effect on rates of ESRD.
Mortality is high among patients receiving renal repla-
cement therapy with an 8% mortality rate in the first 90
days [10]. In Singapore, survival during the first year of
dialysis is 89.3% and 58.7% after a period of 5 years [9].
Risk factors for mortality include older age, physical and
nutritional impairment, smoking, prior myocardial
infarction, low serum albumin levels at baseline, catheter
access at first dialysis, concomitant cancer, heart failure,
depression, HIV/AIDS, lung disease, neurological dis-
ease, psychiatric conditions and late referral to a
Nephrologist [11,12].
Cardiovascular disease (CVD) accounts for approxi-
mately 50% of all deaths [13]. Dialysis patients are on
average at approximately 30 times higher risk of a fatal
cardiovascular event than the general population, and
this risk still remains 10 to 20 times higher after stratifi-
cation for age, gender and diabetes [13]. This burden of
CVD has been associated with both traditional risk fac-
tors such as smoking, diabetes, hyperlipidaemia, hyper-
tension and physical inactivity and non-traditional
chronic kidney disease-associated factors such as anae-
mia, hyperhomocystenaemia, oxidative stress and bioin-
compatibility [14]. Several investigators have identified
associations between elevated serum phosphate, calcium
× phosphate product, parathyroid hormone and death in
hemodialysis patients [15]. Interventions that lower
serum phosphate levels and thereby delay the develop-
ment of secondary hyperparathyroidism may reduce car-
diovascular mortality.
Hemodialysis requires radical lifestyle changes includ-
ing regular attendance at the dialysis unit for treatment,
restrictions in fluid intake, changes to diet and medica-
tion intake. Estimates within the haemodialysis popula-
tion suggest that the prevalence of non-adherence is
between 10% to 60% for fluid intake, 2% and 57% for
dietary advice, between 0 and 35% skip or shorten dialy-
sis sessions and between 19% and 99% are non-adherent
to their medications [16]. This is likely to be associated
with psychosocial variables such as patients’ beliefs
about medication, social support, and personality char-
acteristics rather than clinical or sociodemographic vari-
ables [17,18]. Poor adherence can have a significant
impact on the risk of morbidity and mortality. In one
large scale study, when compared to compliant patients,
those who skipped one or more hemodialysis sessions in
a month had 5.7% greater interdialytic weight gain and
higher serum phosphate levels. Those who had shor-
tened the duration of 3 or more of their hemodialysis
sessions over the period of one month had a between a
13% and 35% higher risk of death [19]. It has been esti-
mated that each 1-mg/dL increment in phosphate level
increases relative and cardiovascular mortality risk by
5% and 10% respectively [20,21]. Especially when phos-
phate levels are > 5.5-6.0 mg/dL, mortality risks start to
increase considerably [21,22].
Self management interventions offer an effective tool
to support adjustments to the lifestyle changes required
in hemodialysis. For self management to be effective, it
needs to encompass the patient’s ability to monitor their
condition and to affect the cognitive, behavioural and
emotional responses necessary to maintain a satisfactory
QoL [23]. There are 5 core self managements skills; pro-
blem solving, decision making, resource utilization,
forming of a patient/heath care provider partnership
and taking action [24].
Although there is evidence to suggest both clinical and
psychological benefits resulting from self management
interventions in chronic conditions such as arthritis, dia-
betes and recurrent lower urinary tract infections
[25-27], there is comparatively less work on the value of
self management programs in renal disease.
Cross sectional research within the Chronic Kidney
Disease (CKD) population [28] and with kidney trans-
plant patients [29] has shown that perceived self efficacy
is a more consistant correlate of the performance of self
management behaviours than clinical and demographic
variables. In addition engagement in self management
behaviours has been associated with improved QoL [30].
There have however been very few randomised con-
trolled trials assessing the impact of self management in
hemodialysis. Adaptation training and patient empower-
ment programs with patients on hemodialysis have been
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shown to reduce perceived stress, depression and
improve self care self-efficacy and QoL at 3 to 6
months post intervention [31-33]. A group based inter-
vention using cognitive behavioural techniques to
enhance effective self management of fluid consump-
tion has also been shown to improve interdialytic
weight gains although these effects were evident only
at 14 weeks follow up [34]. Although these studies
suggest that psychosocial interventions increase adher-
ence and improve success in self-care in the context of
hemodialysis, most have been underpowered, the inter-
ventions are poorly described, follow up duration is
limited and rigorous evaluation through the inclusion
both clinical and psychological outcomes data are lack-
ing. Reviews have also criticized these studies for not
describing in detail the required training, content or
theoretical background for the intervention and inter-
vention delivery and fidelity [35-38].
The proposed study will address weaknesses of pre-
vious research by recruitment of a sufficiently large and
representative hemodialysis sample, the development of
a well designed theory driven and evidence based inter-
vention and the inclusion of validated assessments of
both clinical and psychological outcomes up to 9 months
post intervention. In doing so this trial will provide
much needed data on the efficacy of self management
interventions with respect to clinical and psychological
outcomes that can inform clinical practice and health
care services.
This paper describes the design, setting, intervention
and outcomes of the NKF-NUS program, a 36 month
cluster randomised trial of self-management support
program for prevalent hemodialysis patients.
Study Objectives
1. To implement a group based self management inter-
vention for patients on hemodialysis
2. To undertake an evaluation of this self management
intervention comparing it with “standard care”. The pri-
mary aim is to determine the efficacy of the self man-
agement intervention on biochemical markers of clinical
status and adherence. Secondary aims are to determine
the effect impact on QoL, mood, self-efficacy and
patient satisfaction.
Methods/Design
Trial design
The study design (Figure 1) is guided by the CONSORT
statement [39]. The NKF-NUS Study is a 3 year prag-
matic cluster randomized clinical trial to evaluate
whether hemodialysis patients benefit from a self man-
agement intervention. The study protocol has been
approved by the NUS Institutional Review Board and is
in compliance with the Helsinki declaration.
Participants will be randomized based on dialysis shift
within each of the participating NKF dialysis centres
into one of two groups;
Group 1: Standard care control group - care currently
received by patients as defined by the National Kidney
Foundations Clinical Practice Guidelines. All healthcare
resources used and advice given to prevalent patients
relating to their kidney failure and its treatment will be
standardised.
Group 2: Group based self management intervention
Patients from both arms will be assessed with the
same measures and at the same time intervals over the
study period.
Setting and Centre Recruitment
The study will be conducted at the National Kidney
Foundation (NKF) dialysis centers, Singapore. There are
24 NKF dialysis centres in Singapore providing hemo-
dialysis to more than 2100 ESRD patients. These are
located throughout the island to ensure easy community
access to patients residing in different parts of Singa-
pore. NKF Dialysis centres are nurse led with a multidis-
ciplinary team of renal consultants, medical social
workers, dieticians and exercise specialists on rotation.
Of these 14 NKF dialysis centres will be included in
the program. Although random selection of dialysis cen-
tres would have been preferable this was not an option
due to the lack of facilities in their excluded dialysis
centres to either host the intervention in situ or their
considerable distance to other dialysis centres with avail-
able facilities. Location and proximity to intervention
venues was an important parameter to take into account
as the intervention sessions are scheduled over week-
ends and hence require substantial commitment on the
part of patients and dialysis centre staff.
Participants
The senior nurse manager in each of participating dialy-
sis centres, will screen patients for eligibility and provide
a list of eligible patients and their preferred language of
communication to the research coordinator. A research
assistant (RA) proficient in the patients’ preferred lan-
guage of communication (e.g. English, Mandarin, or
Malay) will then approach eligible patients for participa-
tion. Participants will be given an information sheet
outlining the details of the study and the RA will subse-
quently verbally explain the study procedures and
requirements, and provide clarifications as needed.
Following written informed consent, participants will
be requested to undertake a baseline assessment (Time
1) (comprising the self report questionnaires listed in
the following section) prior to group allocation (inter-
vention vs. control). Follow up assessments will be
taken immediately after the end of self management
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intervention (Time 2) and at 3 months (Time 3) and 9
months post intervention (Time 4) (See Figure 1).
Inclusion criteria are:
(1) Chronic Kidney Disease patients who have been
receiving hemodialysis for at least 6 months
(2) Aged 21 and over
(3) Patients willing to attend all sessions of the self
management programme.
Exclusion criteria are:
(1) Newly established on hemodialysis (< 6 months)
Figure 1 Flow Chart of Study Design.
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(2) Unable to give informed consent
(3) Unable to understand spoken English and/or Man-
darin, Malay, Tamil dialects to allow effective communi-
cation with the intervention facilitator(s) and/or
Research assistants
(4) A diagnosis of functional psychosis or organic
brain disorder
(5) Impaired cognition
(6) Major visual or hearing impairments, or other sen-
sory or motor impairments that may prohibit comple-
tion of the scheduled assessments
(7) Unable to participate in a group program (e.g.
housebound)
(8) Limited life expectancy due to co-morbid illness
such as malignancy
Randomization
Cluster randomization will take place whereby patients
within the participating dialysis units will be randomised
according to the days on which they receive dialysis. For
example, within a centre those dialysing on Monday,
Wednesday and Friday will receive the intervention and
those dialysing on Tuesday, Thursday and Saturday will
serve as controls. This will prevent cross contamination
of information between groups, a problem encountered
when studying participants who spend large amounts of
their time together in a closed environment.
Once a block of 30 participants have provided
informed consent and completed baseline assessment,
randomization will be performed by the study coordina-
tor, using a computerized method to avoid assignment
bias. Due to the nature of the study and in common of
studies if this type, patients will not be blinded to their
group allocation. Primary outcome measures will be
assessed by a research associate blinded to treatment
allocation and uninvolved in consenting and the man-
agement of the patients. Health care professionals and
dialysis personnel involved in patients’ care will also be
blind to group allocation. It is not however deemed pos-
sible to keep project staff tracking data collection for
secondary outcomes (self reported outcomes) blinded to
condition so the trial will only have double blind accu-
racy with respect to primary outcomes. However, as
questionnaire assessments are by self-report, rather than
rated by a member of the research team, significant
influences of observer biases are not expected.
Participant withdrawal of consent to research follow-up
If a participant withdraws their consent whilst in the
trial, one of the study team will contact the participant
to determine if they are willing for the data they have
given up to that point to be included in the trial. No
data will be used in the analysis without a participant’s
consent.
Sample calculation
Using serum phosphate levels as a physiological index of
adherence to diet and medication) and Kidney disease
specific QoL as primary outcomes, a total sample size of
126 and 128 respectively, were calculated. This was using
80% power (alpha = 0.05) to detect a significant absolute
change of 1.5% in phosphate control and of 5 points (0.5
standard deviation) in the physical and mental compo-
nent subscale scores in kidney disease QoL short form
questionnaire [40]. Taking the larger number of 128 par-
ticipants (64 in intervention and 64 in control group), a
final total number of 154 participants (77 in each group)
is needed to ensure at least an 80% final response rate is
met (attrition/drop-out rate estimated at 20%). A target
sample of 154 participants will be sought.
Measures
The following demographic information will be collected
before the start of the trial: age, gender, ethnicity, educa-
tion, religious affiliation, marital and employment status,
perceived work ability and household income, length of
time since diagnosis, prescribed drugs currently taken,
and co-morbid medical conditions.
Primary outcome measures
Beginning at baseline (Time 1) and continuing into fol-
low up (Time 2, Time 3, Time 4) regular chart reviews
will be conducted to abstract clinical, laboratory, and
pharmacological data including:
(1) Interdialytic weight gain: The amount of weight
gained between the end of one dialysis session and the
beginning of the next. This is a validated marker of
adherence to fluid restriction/regulation.
(2) Blood pressure
(3) Serum phosphate and calcium × phosphate pro-
duct indicating a patient’s adherence to prescribed oral
phosphate binder medications and dietary phosphate
restriction.
(4) Serum potassium indicating adherence to dietary
recommendations.
Other Clinical Measures
(1) Medical notes will be also reviewed to record other
serological data (urea, creatinine, hemoglobin, intact
parathyroid hormone and albumin as well as urea
reduction ratio and Kt/V), all prescribed medication and
relevant information regarding dialysis history and dialy-
sis related events (e.g. access complications) during the
study period.
(2) Attendance for dialysis (skipping and shortening
behaviours) and Health services utilization (number
of admissions, emergency room visits) will also be
monitored.
(3) The End Stage Renal Disease Severity Index
(ESRD-SI) [41] will provide a measure of co-morbid ill-
nesses and other complications of ESRD.
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(4) The Charlson Comorbid Index (CCI) will be used
to consolidate comorbidity burden. CCI scores will be
computed pursuant to the methods described by Bed-
dhu et al. [42].
Secondary process and outcome measures
The potential benefits of the intervention are quite
broad, so multiple secondary outcomes are of interest
and will therefore be measured with the following self
report questionnaires. License agreements have been
obtained for all measures. When no standardized trans-
lations of the instruments are available, translation
validity will be confirmed using forward-backward
method.
(1) QoL as assessed using the Kidney Disease QoL
Short Form - KDQoL-SF [43]. This measure con-
tains the Short form 36 health survey questionnaire
(SF-36) supplemented with scales targeted at parti-
cular concerns of individuals with kidney disease:
symptoms, effects of kidney disease on daily life,
burden of kidney disease, cognitive function, work
status, sexual function, quality of social interaction
and sleep. To minimize burden of completion the SF
36 of the scale has been replaced with the SF12, a
shortened validated version of SF36 to gather infor-
mation on eight health concepts: physical function-
ing, role limitations due to physical and emotional
health, mental health, bodily pain, general health,
vitality and social functioning. These items are then
scored using a norm-based method providing a com-
ponent summary scale score for both mental and
physical Health Related Quality of Life [44]. The
instrument has been proved reliable and valid in dia-
lysis patient populations in Singapore [45].
(2) Generic/Global quality of life was assessed using
the World Health Organization Quality of Life ques-
tionnaire (WHOQOL-BREF) [46]. It is a self-report
inventory of generic QoL consisting of 26 original
items. The items fall into four domains: a) Physical
Health, b) Psychological Health, c) Social Relation-
ships and d) Environment, while two items provide a
measurement of an Overall QoL/Health facet. The
scale has demonstrated good psychometric proper-
ties. It is rated on a 5-point Likert scale and the
range of scores is between 1-20 with higher scores
indicating better quality of life.
(3) Anxiety and depression according to the Hospital
Anxiety and Depression Scale (HADS) [47]. This is a
widely used, self-administered questionnaire specifi-
cally developed to detect anxiety and depression
states in hospital and medical out-patient clinic set-
tings with good reliability and responsiveness [48]. It
is composed of two 7-item scales, one for anxiety
and one for depression. The original English version
has been translated into and validated in many lan-
guages, including Chinese [49,50].
(4) Self-efficacy will be assessed using 2 measures:
one is specific to dialysis patients and the self effi-
cacy for managing chronic disease scale [51]. The
latter comprised the sum of self-efficacy for mana-
ging the general demands of chronic disease.
Respondents rated their confidence for performing
various chronic disease self-management tasks
including, seeking information about their condi-
tions, obtaining help from others and communicat-
ing with physicians, maintaining role function, and
managing symptoms.
The dialysis specific Self-Efficacy Scale [27] was
devised specifically for the purposes of this study.
Respondents are asked to indicate their level of con-
fidence in managing dialysis specific demands related
to diet, fluid intake and medication using eight items
scored on 10 point likert rating scale ranging from
‘not all confident’ to ‘totally confident’ in line with
the Self efficacy for managing chronic disease scale
[51]. An expert panel of renal health professionals
has reviewed the items and the scale was successfully
piloted with a small group of hemodialysis patients
(N = 4).
(5) The Health Education Impact Questionnaire
(HEIQ™) is a reliable measure with high construct
validity, designed to evaluate outcomes from patient
education and self-management interventions for
people with chronic conditions. It comprises eight
domains to assess more proximal program outcomes
[52]; Health directed behaviour, Positive and active
engagement in life, Emotional well-being, Self moni-
toring and insight, Constructive attitudes and
approaches, Skill and technique acquisition, Social
integration and support, Health service navigation.
(6) The Renal Adherence Attitudes Questionnaire
(RAAQ) [53] - The RAAQ is a 26-item scale mea-
suring general attitudes toward compliance. The
scale is composed of Likert-type statements, which
measure a patient’s attitudes toward social restric-
tions, well being, self-care/support and acceptance.
(7) The Renal Adherence Behaviour Questionnaire
(RABQ) [53]- The RABQ comprises 25 items mea-
suring self-reported dietary and fluid intake compli-
ance. Specific dimensions; include compliance to
fluid restrictions; compliance regarding potassium
and phosphate restrictions, compliance regarding
self-care; compliance regarding sodium intake; and
compliance in times of particular difficulty.
(8) Beliefs about medication [54]. The measure com-
prises two 5-item sub-scales assessing beliefs about
the necessity of prescribed medication (‘necessity’
sub-scale) and concerns about prescribed medication
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based on beliefs about the danger of dependence and
long-term toxicity and the disruptive effects of medi-
cation (’concerns’ sub-scale).
(9) The Medication Adherence Report Scale
(MARS). The five-item MARS asks respondents to
rate the frequency with which they engage in non
adherent behaviors (e.g., deciding to miss a dose,
forgetting to take a dose). Scores for each of the five
items are summed to give a total score ranging from
5 to 25 where higher scores indicate higher levels of
self-reported adherence [55].
(10) Six items developed for the study will be
included to measure frequency of non adherent
behaviours to dietary recommendations (3 items)
and fluid intake (3 items) (e.g. forgetting, adjusting).
(11) Qualitative assessment
The trial also includes a qualitative sub-study. The
qualitative research involves in-depth interviews of
intervention participants at 3 and 9 months after
delivery of the NKF-NUS self management course.
The aim of this work is to explore participants’ atti-
tudes towards the program, their satisfaction with
content, delivery and duration and their progress
with regards to self management.
Participants will be asked to describe whether they
have tried making any changes in their fluid intake,
diet and general lifestyle or thinking as a result of
the intervention; whether these changes have been
made successfully or unsuccessfully and the reasons
why. Participants will also be asked to highlight the
strengths and weaknesses of the intervention and to
give feedback on the program in five open-ended
questions.
A short intervention evaluation questionnaire devel-
oped for the purposes of the study will also be admi-
nistered at the 3 and 9 month follow up to rate
patients’ satisfaction with the content, length, deliv-
ery of individual sessions, dynamics and interaction
with the facilitators and with other patients in the
group.
NKF- NUS Hemodialysis Self management Intervention
The NKF NUS hemodialysis self management program
is based on the UCL diabetes self management program
[27,56] but adapted to meet the needs of the target
hemodialysis population in the local context. It empha-
sises patients’ central role and responsibility in mana-
ging their illness. The program offers the potential for
people to learn about their condition and treatment in a
psychologically motivating and confidence enhancing
structure - emphasis is on empowering patients to make
choices and lifestyle changes in line with treatment
recommendations through the use of problem solving,
goal setting and feedback.
The NKF-NUS hemodialysis self management pro-
gram has been developed after widespread consultation
with patients and health care professionals using focus
groups and in depths interviews.
The group based intervention consists of three main
sessions held every two weeks and one booster session
(a total of four 90 minute long sessions each with a
15 minute refreshment break halfway through). Sessions
are facilitated by two health care professionals with
experience of working with dialysis patients (medical
social worker, renal nurse, renal dietician and/or psy-
chologist). This has been planned to ensure assimilation
of the self management program into existing renal ser-
vices. Table 1 summarises program content.
Sessions in the program are based on psychological
theories and techniques that have previously been
employed to enhance and maintain health behavior
change [57,58]. Intervention components will include
problem solving, overcoming barriers, challenging
beliefs, conducting brainstorming sessions, goal setting,
and reinforcement and group processes. These self-
management techniques are taught by means of skills
mastery through biweekly action planning and feedback
on progress, modeling of self-management behaviours
and problem-solving strategies, and social persuasion
through group support and guidance for individual self-
management efforts. Targeted behaviours will include
fluid control, diet, medication and/or exercise.
Patients are required to implement the coping-strate-
gies taught from each session between sessions. Each
session will be broadly structured to consist of a brief
introduction to the theme, elicitation of patients’ views
on the topic, addressing of misconceptions, group dis-
cussion of possible coping strategies, identification of
barriers to change, training in specific management stra-
tegies, drawing up of individual goals to be achieved,
formulating actions plans to achieve these goals and
reviewing previously set goals.
Patients will be contacted by telephone 2 months post
intervention by one of the group facilitators (either psy-
chologist, nurse or social worker) to assess the progress
they are making with their goals. This will provide an
ongoing interaction between the healthcare professional
and the patients and will thereby represent an additional
support system. A booster session will also be provided
for participants 3 months after completion of the initial
intervention. This will allow patients the opportunity to
review their progress, address maintenance of beha-
viours over time and explore reasons for success and
failure. The booster session will also remind patients of
the principles of self management, problem-solving,
action planning and will provide revision of important
behavioural areas and reset goals. This booster session
will be led by the same group facilitators.
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Missed sessions
If participants do not attend a session they will be sent
any missed materials and, where possible, the session
will be held over the telephone by one of the facilitators.
Participants receiving the intervention will continue to
have access to services available as part of their usual
health care
Delivery of intervention
To implement the proposed self management interven-
tion, a number of healthcare professionals including
renal nurses, renal dieticians and medical social workers
already working extensively with the renal patient popu-
lation in the National Kidney Foundation will be trained
in the self management principles required for delivery
of the intervention. This will allow the facilitators to run
group sessions using the self management skills of pro-
blem solving, decision making, resource utilization, for-
mation of patient/heath care provider partnerships and
taking action. This program will be formulized in a
manual with an accompanying training course, thereby
facilitating rollout across the health/renal services and
enabling any benefits accruing in the study to be broadly
implemented.
Quality assurance and Fidelity of Intervention
Fidelity rating for the intervention will first be evaluated
in the preliminary phase of supervised pilot sessions; this
consists of 4 pilot groups which will be scheduled to
complete prior to the main trial to enable further training
for facilitators. Intervention consistency and quality will
also be assessed throughout the trial. A random subset of
the intervention sessions will be observed. The delivery
of the intervention will be evaluated using a criterion
based checklist for each session. The criteria will include
assessment of intervention techniques used (e.g. rapport
building, problem solving, reinforcement) as well as a
checklist against the content objectives for each session
(e.g. whether facilitators kept to their roles and how well
they explained/guided participants on setting goals).
Summary notes from those facilitating the sessions will
also be collated for further analysis. A sub-sample of the
intervention facilitators will be asked to participate in a
brief semi-structured interview to understand their
experience of the intervention and their perceived com-
petence in delivering and facilitating the session. Finally
structured notes (e.g. how long each session, where it
was delivered, etc.) will be collected to ascertain the effect
of various setting and contextual factors.
Table 1 Summary of Content of the NKF-NUS self management program
Session Topic Content
1 Fluid intake General introduction to program; expectations;
Introduction to fluid regulation; barriers to fluid regulation; problem solving; goal setting on
fluid intake
2 Diet Feedback on progress
Review and revise goals from session 1.
Introduction to Healthy eating in the context of ESRD; Difficulties related to diet; problem
solving, goal setting on diet
+ BROCHURE ‘Healthy eating for people of dialysis’
3 Medication * Feedback on progress
Review and revise goals on diet and fluid
Introduce to medication for patients on dialysis; barriers to taking medication; problem
solving; goal setting on medication.
Discussing potential/preventing Goal Lapses
Dealing with Goal Lapses
+ BROCHURE ‘process of problem solving’
* Exercise [only if group has no issues
with medication]
Introduce exercise for patients on dialysis; Barriers to exercise; problem solving’ goal setting on
exercise
Telephone follow up Feedback on progress
Review and revise goals
4 Booster session Group activity to revisit program topics; revisiting expectations
Feedback on progress; Review and revise goals
Use problem solving to overcome problems
Lapses, relapses and maintenance of behaviour
Maintaining changes over time
Goal Setting
+ BROCHURE ‘process of problem solving’
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A trial steering group will meet at regular intervals
throughout the trial and advise on any issues that arise.
The senior research team will provide feedback and sup-
port to the data collection and intervention facilitators’
teams.
Statistical Considerations
Outcomes will be analysed immediately after the inter-
vention and then at 3 and 9 months
separately on an intention to treat basis. Analyses of cov-
ariance (ANCOVAs) will be performed for each outcome
to examine changes within groups (Intervention vs. stan-
dard care control) comparing baseline to follow-up assess-
ments. Covariates used will include baseline levels and
other casemix differences between the groups (if any). The
statistical significance criterion will be set at P < 0.05.
In addition to this intention-to-treat analysis we will
also undertake a “per protocol” analysis on those indivi-
duals who attended all of the educational sessions in the
intervention arm.
No formal subgroup analyses are planned. However
exploratory analysis of the impact of patient level factors
(e.g. age, gender, ethnicity and time on dialysis) on the
effect of the intervention will be carried out.
Data management
Each participant will be assigned a unique numeric
study code at the beginning of the trial so that they can
be tracked anonymously throughout. The trial data will
be entered onto a SPSS spreadsheet by an administrator.
A random 10% sample of data will be checked for
accuracy.
The qualitative interview will be audio-taped or digi-
tally recorded. Interviews will be transcribed by an
administrator, omitting any information that may com-
promise confidentiality. All audio-tapes will then be
destroyed and all electronic transcripts kept on a pass-
word protected computer. These will only be made
available to those within the research team and any
identifiers within the transcripts will be removed so that
the data cannot be traced back to the participants. All
personal data is stored on an encrypted drive, and links
to personal information are available only to research
investigators and trial coordinator. Consent forms and
questionnaire data are double-entered and stored in
locked filing cabinets in a secure site at National Uni-
versity of Singapore.
Discussion
Worldwide, the shift within health services to a more
patient centered approach has underlined the necessity
of engaging people in their own health. In long term
conditions this shift has the potential of providing large
benefits to patients and to improve clinical outcomes.
Patients on dialysis are required to make a number of
major lifestyle changes and the NKF-NUS self manage-
ment intervention has been designed to empower
patients to take control of their condition.
The trial will evaluate the effectiveness of a brief self
management intervention delivered in groups of estab-
lished hemodialysis patients to improve biological mar-
kers of adherence and psychosocial functioning
compared to standard care.
Previous research indicates the effectiveness of psy-
chological interventions in clinical and psychosocial out-
comes [35-37] but has methodological limitations
related to sample size and short duration of follow up.
The current trial is the first to evaluate the effects of a
theory driven self management intervention in Singa-
pore, in a program delivered by health care professionals
rather than trained psychologists. Given the scaricity of
trained psychologists in renal services in Singapore, the
adopted approach of training existing renal health care
professionals already involved in the care of people on
hemodialysis maximises potential feasibility of the inter-
gration and delivery in the NKF centres across Singa-
pore. The intervention is fully manualized and
supported by a training course ensuring that it can be
replicated in a standadized form.
The trial design addresses weaknesses of previous
research by use of an adequate sample size to detect
clinically significant changes in biochemical markers,
recruitment of a sufficiently large and representative
haemodialysis sample, definition of a feasible theory
based intervention to support treatment adherence, and
careful assessment of both clinical and psychological
endpoints in order to evaluate whether effects (if any)
are sustained over time. Inclusion of multiple dependent
variables allows us to assess the broader impact on the
intervention including both hard end points as well as
patient reported outcomes. A further strength of the
trial design is the inclusion of measures that explore the
extent to which the intervention impacts upon psycho-
logical processes and how these processes act as mediat-
ing variables. It will be possible to explore whether the
intervention influences beliefs and cognitions (self effi-
cacy expectancies). It will also be possible to examine
whether differences in clinical outcomes and behaviours
are due to intervention effect on beliefs and cognitions.
The current trial does however pose a number of
challenges, perhaps most notably related to the potential
of recruitment bias. We have purposefully selected NKF
community dialysis centres across Singapore to ensure
geographical representation, however, certain dialysis
centres were not approached due to the lack of facilities
to host the intervention or distance from other dialysis
centres with such facilities. Although it would have been
preferable to randomly select units among the 24 NKF
Griva et al. BMC Nephrology 2011, 12:4
http://www.biomedcentral.com/1471-2369/12/4
Page 9 of 11
centres, this was not deemed feasible in this pragmatic
trial. As no differences in sociodemographic or ethnic
composition of patients across centres/residents in dif-
ferent regions in singapore is expected due to imple-
mentation of hosing policies to ensure adequate
representation of ethnic groups is public housing pro-
jects [59], we feel that this approach will not introduce
bias. We will however examine statistically any differ-
ences between participating and non participating cen-
tres as well as between dialysis shifts in the participating
centres. Active steps will be taken to reduce a variety of
potential biases through the use of randomisation
procedures.
The trial is mainly generalisable to patients who are
willing to participate and be randomised and to patients
who can competently converse into either English, Man-
darin and/or Malay. Patients preferred language of com-
munication will be taken into consideration when
forming groups but there are no resources to allow
delivery of intervention in patients who only speak dia-
lects (e.g. Hokkien, Teochew) or Tamil. Exclusion of
these patients is therefore unavoidable. Participants
excluded due to language barriers and control partici-
pants will have an opportunity to participate in the pro-
gram at the end of the trial.
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